

Oslo Stock Exchange

Box 460 Sentrum,
0105 Oslo,
Norway

TEL: +353 1 223 1447

17 May 2021

Securities Regulation of 29 June 2007 ("STA") - Disclosure of Significant Shareholding

Dear Sir/Madam,

In the name and on behalf of FIL Limited, Pembroke Hall, 42 Crow Lane, Pembroke, HM19 Bermuda, (the "Investment Manager") we hereby notify you pursuant to STA Chapter 4, Section 4-1 the following:

On 14 May 2021 the shares and rights to shares in Ultimovacs ASA (the "Company") attributable to the Investment Manager crossed below the threshold of 5%.

The threshold was crossed by means of a Sale of 30,453. shares.

Therefore, the total shareholding deemed to be held is 1,579,549 which represent 4.93% of the shares outstanding and voting rights of the Company.

The shares and rights to shares are owned by the funds listed on Schedule A and are managed by the designated management companies which are undertakings controlled by the Investment Manager.

If you have any questions with respect to this notification, please contact Paul Clark, Regulatory Reporting Manager, at +353 1 223 1447 or via email fil-regreporting@fil.com.



Paul Clark

Manager, Regulatory Reporting

Duly authorized under Powers of Attorney effective May 23, 2017 by Allan Pelvang by and on behalf of FMR LLC and its direct and indirect subsidiaries.